Liver Cancer Drug Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Liver Cancer Drug Market 

5.1. COVID-19 Landscape: Liver Cancer Drug Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Liver Cancer Drug Market, By Drug Type

8.1. Liver Cancer Drug Market Revenue and Volume, by Drug Type

8.1.1. Targeted Therapy

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Immunotherapy

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Chemotherapy

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Combination Therapy

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Liver Cancer Drug Market, By Mechanism of Action

9.1. Liver Cancer Drug Market Revenue and Volume, by Mechanism of Action

9.1.1. Tyrosine Kinase Inhibitors

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Checkpoint Inhibitors

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Monoclonal Antibodies

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Anti-Angiogenic Agents

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Liver Cancer Drug Market, By Formulation 

10.1. Liver Cancer Drug Market Revenue and Volume, by Formulation

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Injectable

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global Liver Cancer Drug Market, By Application

11.1. Liver Cancer Drug Market Revenue and Volume, by Application

11.1.1. Advanced Liver Cancer

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Early-Stage Liver Cancer

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Post-Surgery Adjuvant Therapy

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Liver Cancer Drug Market, By End-User

12.1. Liver Cancer Drug Market Revenue and Volume, by End-User

12.1.1. Hospitals

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Specialty Oncology Clinics

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Cancer Research Institutes

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Homecare / Palliative Care

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Liver Cancer Drug Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type

13.1.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.1.3. Market Revenue and Volume Forecast, by Formulation

13.1.4. Market Revenue and Volume Forecast, by Application

13.1.5. Market Revenue and Volume Forecast, by End-User

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type

13.1.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.1.6.3. Market Revenue and Volume Forecast, by Formulation

13.1.6.4. Market Revenue and Volume Forecast, by Application

13.1.6.5. Market Revenue and Volume Forecast, by End-User  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type

13.1.7.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.1.7.3. Market Revenue and Volume Forecast, by Formulation

13.1.7.4. Market Revenue and Volume Forecast, by Application

13.1.7.5. Market Revenue and Volume Forecast, by End-User

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type

13.2.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.3. Market Revenue and Volume Forecast, by Formulation

13.2.4. Market Revenue and Volume Forecast, by Application  

13.2.5. Market Revenue and Volume Forecast, by End-User  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type

13.2.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.6.3. Market Revenue and Volume Forecast, by Formulation

13.2.7. Market Revenue and Volume Forecast, by Application  

13.2.8. Market Revenue and Volume Forecast, by End-User  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type

13.2.9.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.9.3. Market Revenue and Volume Forecast, by Formulation

13.2.10. Market Revenue and Volume Forecast, by Application

13.2.11. Market Revenue and Volume Forecast, by End-User

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type

13.2.12.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.12.3. Market Revenue and Volume Forecast, by Formulation

13.2.12.4. Market Revenue and Volume Forecast, by Application

13.2.13. Market Revenue and Volume Forecast, by End-User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type

13.2.14.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.2.14.3. Market Revenue and Volume Forecast, by Formulation

13.2.14.4. Market Revenue and Volume Forecast, by Application

13.2.15. Market Revenue and Volume Forecast, by End-User

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type

13.3.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.3. Market Revenue and Volume Forecast, by Formulation

13.3.4. Market Revenue and Volume Forecast, by Application

13.3.5. Market Revenue and Volume Forecast, by End-User

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type

13.3.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.6.3. Market Revenue and Volume Forecast, by Formulation

13.3.6.4. Market Revenue and Volume Forecast, by Application

13.3.7. Market Revenue and Volume Forecast, by End-User

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type

13.3.8.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.8.3. Market Revenue and Volume Forecast, by Formulation

13.3.8.4. Market Revenue and Volume Forecast, by Application

13.3.9. Market Revenue and Volume Forecast, by End-User

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type

13.3.10.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.10.3. Market Revenue and Volume Forecast, by Formulation

13.3.10.4. Market Revenue and Volume Forecast, by Application

13.3.10.5. Market Revenue and Volume Forecast, by End-User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type

13.3.11.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.3.11.3. Market Revenue and Volume Forecast, by Formulation

13.3.11.4. Market Revenue and Volume Forecast, by Application

13.3.11.5. Market Revenue and Volume Forecast, by End-User

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type

13.4.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.3. Market Revenue and Volume Forecast, by Formulation

13.4.4. Market Revenue and Volume Forecast, by Application

13.4.5. Market Revenue and Volume Forecast, by End-User

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type

13.4.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.6.3. Market Revenue and Volume Forecast, by Formulation

13.4.6.4. Market Revenue and Volume Forecast, by Application

13.4.7. Market Revenue and Volume Forecast, by End-User

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type

13.4.8.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.8.3. Market Revenue and Volume Forecast, by Formulation

13.4.8.4. Market Revenue and Volume Forecast, by Application

13.4.9. Market Revenue and Volume Forecast, by End-User

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type

13.4.10.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.10.3. Market Revenue and Volume Forecast, by Formulation

13.4.10.4. Market Revenue and Volume Forecast, by Application

13.4.10.5. Market Revenue and Volume Forecast, by End-User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type

13.4.11.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.4.11.3. Market Revenue and Volume Forecast, by Formulation

13.4.11.4. Market Revenue and Volume Forecast, by Application

13.4.11.5. Market Revenue and Volume Forecast, by End-User

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type

13.5.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.5.3. Market Revenue and Volume Forecast, by Formulation

13.5.4. Market Revenue and Volume Forecast, by Application

13.5.5. Market Revenue and Volume Forecast, by End-User

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type

13.5.6.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.5.6.3. Market Revenue and Volume Forecast, by Formulation

13.5.6.4. Market Revenue and Volume Forecast, by Application

13.5.7. Market Revenue and Volume Forecast, by End-User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type

13.5.8.2. Market Revenue and Volume Forecast, by Mechanism of Action

13.5.8.3. Market Revenue and Volume Forecast, by Formulation

13.5.8.4. Market Revenue and Volume Forecast, by Application

13.5.8.5. Market Revenue and Volume Forecast, by End-User

Chapter 14. Company Profiles

14.1. Bayer AG

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Bristol Myers Squibb

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Exelixis, Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Merck KGaA

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eisai Co.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Exelixis, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Eli Lilly and Co.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. GlaxoSmithKline

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Pfizer Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. AstraZeneca

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms